Tedec-Meiji Farma

CompanySpain

Tedec-Meiji Farma develops 4 assets, the furthest in phase 3 (Chondroitin sulfate in knee osteoarthritis). Mostly supplement and small molecule; based in Spain.

4
Assets
Furthest stage
Phase 3
2
Trials
6
Signals

Pipeline

4
  • Chondroitin sulfate

    Sulfated glycosaminoglycan providing cartilage matrix structural support and reducing inflammatory signaling in joints.

    Phase 3, Supplement, knee osteoarthritis, dry eye syndrome

  • Chondroitin sulfate+glucosamine sulfate

    Supports cartilage matrix maintenance and may reduce joint inflammation.

    Phase 3, no development reported, Small molecule, knee osteoarthritis, osteoarthritis

  • glucosamine

    Supports cartilage matrix synthesis and maintenance.

    Phase 3, no development reported, Small molecule, back pain, knee osteoarthritis

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials2
  • Signals20
  • Similar companies6

Intelligence